In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Survodutide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 172 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 37 (37 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 35 · 10 active1 more mentions it but does not test it | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Survodutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 42384 | 969954105 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
| Adverse eventsWhole body | 2424 | 7757723 |
|---|
| Glycemic controlMetabolic and weight | 30237 | 66866512 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1212 | 345345 |
|---|
| Liver fat and liver functionLiver | 29281 | 17917441 |
|---|
| Kidney functionKidney and urinary | 66 | 1361351 |
|---|
| LipidsCardiovascular | 22 | 1181171 |
|---|
| MortalityWhole body | 11 | 1041031 |
|---|
| Blood pressureCardiovascular | 11 | 9999 |
|---|
| Appetite and food intakeNervous system and cognition | 22 | 97952 |
|---|
| PharmacokineticsPharmacology | 33 | 93894 |
|---|
| Inflammation markersKidney and urinary | 11 | 51492 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Survodutide differs from Glucagon at 9 positions.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 35 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Boehringer Ingelheim5,531 participants20 Nov 2023 to 30 Jun 2026
Obesity
Boehringer Ingelheim1,800 participants14 Oct 2024 to est. 27 Dec 2031
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Boehringer Ingelheim1,590 participants12 Nov 2024 to est. 5 Jun 2029
Metabolic Dysfunction Associated Steatohepatitis
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Survodutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −12.2% Mean body weight change · survodutide 3.6 mg Placebo: −5.4% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | −14.9% Mean weight change Placebo: −2.4% Dose studied: 2.4 mg once weekly68 weeksn = 1,9612021 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in percentage points | −0.9 percentage points HbA1c change · survodutide 3.6 mg Placebo: −0.2 percentage points Dose studied: 3.6 mg once weeklyn not reported2026 | |
| Liver fat and liver functionLiverCompared as: share of people in the arm that got the peptide, in % | 47% MASH improvement responders · survodutide 2.4 mg Placebo: 14% Dose studied: 2.4 mg once weekly48 weeksn not reported2024 | 30% Responder proportion · semaglutide 2.4 mg |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 8% Serious adverse events Placebo: 7% Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024 | 47.9% Serious adverse events Placebo: 50.3% Dose studied: maximal dose 14 mg once dailyn = 9,650 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 80.9% Gastrointestinal adverse events · survodutide 3.6 mg Placebo: 47.9% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | 41.8% Gastrointestinal adverse events Dose studied: 1.0 mg once weekly |
−12.2%
Mean body weight change · survodutide 3.6 mg
Placebo: −5.4%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
−14.9%
Mean weight change
Placebo: −2.4%
Dose studied: 2.4 mg once weekly68 weeksn = 1,9612021
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Survodutide | Semaglutide |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h·nmol/l | No comparable result 1 randomized-trial result measure it in another way or another unit. | 233 h·nmol/L AUC0-24h,sema,SS · 3 mg oral semaglutide Dose studied: 3 mg12 weeksn = 32 |
−1.5 % points
HbA1c change
52 weeksn = 1,7482022
Dose studied: 2.4 mg52 weeksn = 1002026
−0.9 percentage points
HbA1c change · survodutide 3.6 mg
Placebo: −0.2 percentage points
Dose studied: 3.6 mg once weeklyn not reported2026
−1.5 % points
HbA1c change
52 weeksn = 1,7482022
47%
MASH improvement responders · survodutide 2.4 mg
Placebo: 14%
Dose studied: 2.4 mg once weekly48 weeksn not reported2024
30%
Responder proportion · semaglutide 2.4 mg
Dose studied: 2.4 mg52 weeksn = 1002026
8%
Serious adverse events
Placebo: 7%
Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024
47.9%
Serious adverse events
Placebo: 50.3%
Dose studied: maximal dose 14 mg once dailyn = 9,6502025
80.9%
Gastrointestinal adverse events · survodutide 3.6 mg
Placebo: 47.9%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
41.8%
Gastrointestinal adverse events
Dose studied: 1.0 mg once weekly56 weeksn = 8132018
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 1 result from other study designs. | −3.84 mm Hg SBP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −18.08% hsCRP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No randomized trial result 6 results from other study designs. | −52.1% UACR change Dose studied: 2.4 mg per week24 weeksn = 1012025 |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | 8% Paracetamol AUC0-5h increase Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
233 h·nmol/L
AUC0-24h,sema,SS · 3 mg oral semaglutide
Dose studied: 3 mg12 weeksn = 322024
No randomized trial result
1 result from other study designs.
−3.84 mm Hg
SBP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
1 result from other study designs.
−18.08%
hsCRP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
2 results from other study designs.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
6 results from other study designs.
−52.1%
UACR change
Dose studied: 2.4 mg per week24 weeksn = 1012025
No randomized trial result
2 results from other study designs.
8%
Paracetamol AUC0-5h increase
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021